Shares of Amicus Therapeutics Inc. (NASDAQ:FOLD) traded up 3% on Wednesday . The company traded as high as $7.74 and last traded at $7.59, with a volume of 1,119,253 shares traded. The stock had previously closed at $7.37.

A number of analysts have recently weighed in on the company. Zacks Investment Research cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 2nd. Chardan Capital set a $15.00 price objective on Amicus Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 11th. Leerink Swann reissued an “outperform” rating and issued a $17.00 price objective on shares of Amicus Therapeutics in a research report on Wednesday, June 1st. Finally, Bank of America Corp. assumed coverage on Amicus Therapeutics in a research note on Wednesday, May 18th. They issued a “buy” rating and a $10.00 target price for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $12.19.

The company’s market capitalization is $992.13 million. The firm’s 50-day moving average price is $6.53 and its 200-day moving average price is $6.87.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by $0.07. Equities research analysts expect that Amicus Therapeutics Inc. will post ($1.35) earnings per share for the current fiscal year.

In related news, insider Jay Barth sold 10,458 shares of the firm’s stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $7.00, for a total transaction of $73,206.00. Following the sale, the insider now owns 15,000 shares in the company, valued at $105,000. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Ellen Rosenberg bought 15,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 2nd. The shares were purchased at an average price of $7.67 per share, for a total transaction of $115,050.00. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in Amicus Therapeutics stock. California Public Employees Retirement System boosted its position in Amicus Therapeutics Inc. (NASDAQ:FOLD) by 3.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 326,100 shares of the biopharmaceutical company’s stock after buying an additional 11,600 shares during the period. California Public Employees Retirement System owned 0.26% of Amicus Therapeutics worth $3,163,000 at the end of the most recent reporting period.

Amicus Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of therapies to treat a range of rare and orphan diseases. Its lead product candidate, migalastat HCl (Galafold), is an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease, which is a type of lysosomal storage disorder (LSD).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.